• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Kimball Electronics (KE) Stock Looks Cheap, But Profit Quality Clouds Upside

    Simply Wall St·08/13/2026 23:42:48
    Listen to the news

    Kimball Electronics stock quietly added 3.3% to close at US$26.03, which hardly suggests major drama for a company that just reported a year in which earnings grew far faster than sales and margins edged higher. The market reaction looks modest next to a 64.8% jump in earnings over the past year and a trailing net margin that has moved to 2.0% from 1.1%.

    The main point of debate is the quality of profit. Reported results still include a US$9.7m one-off gain. At the same time, the core business places more emphasis on cash generation, a lighter debt load and a P/E multiple that sits below sector averages. The rest of the earnings discussion highlights why that gap matters.

    Is Kimball Electronics trading at a genuine discount, or is the lower P/E simply mirroring a patchy profit record and that US$9.7m one off gain distorting the picture? Compare current earnings, cash flows and peer multiples with our valuation analysis for Kimball Electronics

    FY 2026 Earnings Summary

    • Revenue (Q4 FY 2026 vs Q4 FY 2025): US$371.6m vs. US$380.5m (down about 2%)
    • Net Income (Excl. Extra Items, Q4 FY 2026 vs Q4 FY 2025): US$8.5m vs. US$6.6m (up about 30%)
    • Basic EPS (Q4 FY 2026 vs Q4 FY 2025): US$0.35 vs. US$0.27 (up about 31%)
    • Adjusted Operating Margin (Q4 FY 2026 vs Q4 FY 2025): 4.9% of sales vs. 5.2% of sales (slight margin compression)

    Prefer clean charts instead of another wall of earnings tables and margin percentages? Get a full visual picture of Kimball Electronics, with an at-a-glance valuation breakdown in the company report for Kimball Electronics..

    NasdaqGS:KE Trailing 12-Month Earnings & Revenue History as at Aug 2026
    NasdaqGS:KE Trailing 12-Month Earnings & Revenue History as at Aug 2026

    Kimball Electronics Starts to Validate Medical Growth Story

    The bullish view on Kimball Electronics hinges on Medical CDMO becoming a larger, higher quality growth engine supported by automation and tighter integration. The latest results start to back that up. Medical revenue reached US$109m in Q4, about 29% of company sales, with FY 2026 growth above 10% once a one time consigned inventory sale in FY 2025 is excluded. Management now expects Medical to approach roughly 35% of revenue in FY 2027. That is a clear step toward the mix shift the thesis called for.

    Operations are also hitting some of the milestones behind that story. The Indianapolis facility is progressing, Helvoet is folded in with early cross selling traction, and gross margin improved 90 bps year on year even with higher SG&A to support Medical CDMO expansion. Revenue is still only guided to mid single digit organic growth, but the Medical pillar is moving in the direction the bullish narrative anticipated.

    Compare whether this Medical CDMO momentum and margin progress at Kimball Electronics lines up with what Wall Street is expecting. See the consensus price target analysis for Kimball Electronics to gauge how analyst targets stack up against the latest earnings story.

    Kimball Electronics Bear Case Finds Fresh Support

    The bearish view on Kimball Electronics centers on margin pressure, capital intensity and customer concentration risk. This quarter gives that view fresh backing. Revenue slipped 2% year on year, while adjusted operating margin eased to 4.9% from 5.2%, even as Medical grew and gross margin improved. That supports the concern that higher SG&A and ongoing pricing pressure are offsetting mix and efficiency gains.

    Bears also worry that heavy and recurring capital expenditure could strain free cash flow if growth slows. Guidance for FY 2027 CapEx of US$50m to US$60m, alongside only 3% to 5% organic growth, fits that concern rather than defuses it. Medical reached 29% of sales and is guided higher, yet automotive and industrial both declined year on year, and steering remains about 70% of automotive revenue. That concentration keeps the risk of volume shocks very much alive.

    After earnings fuelled by one off items and heavy CapEx plans, review whether Kimball Electronics faces deeper structural issues in our risk analysis for Kimball Electronics which shows 1 important warning sign.

    Stay Ahead With Simply Wall St

    If the mix of Medical CDMO momentum, one off gains and CapEx plans at Kimball Electronics has your attention, register for free with Simply Wall St and add it to your Watchlist to track price moves against fair value and wait for an entry point that fits your plan. After you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the most important portfolio level developments. For a longer term view, tap into the crowd insight inside the Community and see how other investors are interpreting the same data. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market rather than reacting to it late.

    Seeking Alternatives Beyond Kimball Electronics

    Fresh stock ideas can move from quiet potential to full breakout before most investors even notice. Use these curated lists while the data is still under the radar for now and act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.